Community Target Request
Sequence Information
Organism:
Acanthamoeba
Arenaviruses
Babesia
Bartonella
Borrelia
Brucella
Burkholderia
Coccidioides
Cryptosporidium
Cyclospora
Ehrlichia (Anaplasma)
Encephalitozoon
Entamoeba
Erythrovirus
Filoviridae
Giardia
Hantavirus
Henipavirus
Homo
Influenzavirus
Lyssavirus
Mycobacterium
Nairovirus
Orthobunyavirus
Other
Phlebovirus
Rickettsia
Rubulavrius
Toxoplasma
UniProt ID:
UniProt description:
UniProt sequence:
Not in UniProt?
Hyperlink to webpage with sequence:
No identifier available?
Annotation:
DNA Sequence
Area of biomedical interest
Required: Make only 1 choice, select most relevant
Known drug target – The gene product is the target of a drug which is currently on the market or in development. Minimally, inhibitors of the target will have been shown to block cell growth in the genus/species listed.
Potential drug target – An ortholog of a known drug target, an essential gene or a homolog of an essential gene.
Targets associated with virulence and/or pathogenesis- A gene product associated with pathogen adhesion, colonization, invasion, immune response inhibition or toxicity of the host cells.
Vaccine candidate- A gene product identified as a vaccine candidate.
Targets involved in drug resistance- The gene product is confirmed or suggested to be involved (directly or indirectly) in drug-target binding, drug degradation or drug removal all of which result in evolution over time of drug resistance.
Targets showing phylogenetic evidence for essentiality, virulence or pathogenesis- Targets for which orthologues present in a pathogenic species/strain and absent in a non-pathogenic species/strain.
Targets associated with innate immunity- Human proteins associated with non-adaptive immune mechanisms that recognize, and respond to, microorganisms, microbial products and antigens.
Marker of infection- A biomarker, antigen or other protein used to detect pathogen infection.
Targets of other biological interest- targets falling outside the categories described above.
Unknown
Justification
Required: Include a brief (one or two sentence) description of how determination of the target structure will enhance research progress in the field.
Supporting Evidence
Describe supporting experimental evidence and/or relevant literature for functional or biological relevance of the target.
Material Availability
Construct name:
Construct sequence:
Does this construct express soluble protein?:
Yes
No
If yes, how much in mg/ml?
If no, do you have a solubilization protocol and if so, how much protein does the protocol produce in mg/ml?
List any important post-translational protein modifications, additives to improve solubility or purification, known ligands and their availability.
Construct sequence
Expressed Protein sequence
Vector
Tag
List any additional information, e.g. ligands or co-factors bound, etc
Can you provide a minimum of 150 ml at ~5mg/ml soluble protein?
Yes
No
List any important post-translational protein modifications, additives to improve solubility or purification, known ligands and their availability.
Applicant Information
Name (required)
Title
Affiliation
Address 1
Address 2
Address 3
Address 4
City (required)
State
Zip
Country (required)
Phone
Email (required)
Alternate contact
Alternate email
Intellectual Property
I understand that any structures successfully determined by the SSGCID will be submitted to the Protein Data Bank (http:/www.rcsb.org/pdb) and be part of the public domain.
Yes
No
© 2007 Seattle Biomedical Research Institute. All rights reserved.
info@sbri.org